Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 18
Why Dying Liver Cells Drive MASH
A 2026 review explains how cell death fuels MASH, the liver disease semaglutide became the first FDA-approved drug to treat.
GLP-1 Drugs, PCOS, and Stopping Treatment
Some GLP-1 users say PCOS symptoms return after stopping treatment. Here is what the semaglutide and retatrutide trial data actually shows.
Semaglutide and tirzepatide for MASH
Semaglutide now has FDA approval for MASH liver fibrosis, and tirzepatide's phase 2 data suggests a stronger signal is coming.
GLP-1 Drugs and Skin Cancer Risk
A new Dermatologic Surgery paper links semaglutide and tirzepatide to lower skin cancer rates in patients with obesity, but the abstract isn't public yet.
Semax/Selank blend: the dosing math gap
Semax/Selank blend dosing math fails for one reason: the vial never states how much of each peptide it actually contains.
Tirzepatide and Atrial Fibrillation Risk
A new meta-analysis of 10 trials found no significant link between tirzepatide and atrial fibrillation, though the data remain thin and uncertain.
Testing Tirzepatide After Gastric Bypass
A Vanderbilt pilot trial called GRABS is testing tirzepatide in patients whose obesity persists after gastric bypass surgery.
Can you drink alcohol on tirzepatide?
The tirzepatide label lists no alcohol interaction and no trial has tested the combination. Here is where the two sets of risks actually overlap.
CJC-1295 Q3 2026: what actually changed
The FDA's compounding panel voted on seven peptides in July. CJC-1295 was not one of them, and a new June review grades its evidence B and D.
IGF-1, HGH, and tesamorelin: what to know
IGF-1 of 159 ng/mL means little without a baseline and an age-matched range. This article explains what the number means and how tesamorelin differs from HGH.
Incretin malnutrition review explained
A new review of tirzepatide, semaglutide and related trials raises nutrition questions without proving common clinical malnutrition.
What Medicare's GLP-1 bridge may cost
CMS has disclosed Medicare's $50 GLP-1 copay and a manufacturer net price, but not a total taxpayer cost estimate.